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ABSTRACT
Aims/Introduction: We aimed to examine the effect of an angiotensin II receptor
blocker (ARB), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, and
their combination on myocardial fibrosis and function in type 2 diabetic rats.
Materials and Methods: Five male Long-Evans Tokushima Otsuka (LETO) rats and 20
male Otsuka Long-Evans Tokushima Fatty (OLETF) rats were used. OLETF rats were
assigned to four groups (n = 5 per group) at 28 weeks-of-age: untreated, losartan-treated,
rosiglitazone-treated and combination-treated. The ARB, losartan, was administered at a
dose of 5 mg/kg/day, and the PPAR-gamma agonist, rosiglitazone, was administered at a
dose of 3 mg/kg/day by oral gavage for 12 weeks. Urine and blood samples were
collected, and two-dimensional echocardiograms and strain rate imaging were obtained
at 28 and 40 weeks. Cytokines were evaluated by reverse transcriptase polymerase chain
reaction, and histological analysis was carried out at 40 weeks.
Results: At 40 weeks, the global radial strains of the losartan-treated (55.7 – 4.5%,
P = 0.021) and combination-treated groups (59.3 – 6.7%, P = 0.001) were significantly
higher compared with the untreated OLETFs (44.3 – 10.5%). No difference was observed
when compared with LETO rats. Although the rosiglitazone-treated group showed a bet-
ter metabolic profile than the untreated OLETF group, there was no difference in the glo-
bal radial strain (49.8 – 6.0 vs 44.3 – 10.5, P = 0.402). The expression of pro-inflammatory
cytokines, and collagen type I and III were consistently attenuated in the losartan-treated
and combination-treated OLETF groups, but not in the rosiglitazone-treated group.
Conclusions: A combination of rosiglitazone and losartan attenuates myocardial fibrosis
and dysfunction in type 2 diabetic rats.
INTRODUCTION
Patients with diabetes mellitus (DM) are characterized by an
increased likelihood of heart failure1. The mechanisms of myo-
cardial dysfunction in diabetic patients are multifactorial, and
include metabolic disturbances, myocardial ﬁbrosis, small vessel
disease (so-called microangiopathy), autonomic dysfunction and
insulin resistance2. Albuminuria reﬂects a renal and systemic
transvascular albumin leakage; therefore, it has been consid-
ered as a marker of microangiopathy3. Cardiac and vascular
complications progress two- to 10-fold faster in patients with
microalbuminuria or proteinuria compared with subjects with
normal albumin secretion4–7. Diabetic myocardial dysfunction is
more frequently observed in patients with microalbuminuria8–12.Received 7 April 2013; revised 22 August 2013; accepted 26 August 2013
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Furthermore, the degree of albuminuria is closely related to the
severity of myocardial dysfunction in type 2 diabetes13. The
microangiopathic complications of DM usually have a prolonged,
asymptomatic phase characterized by early subclinical functional
and structural abnormalities. These complications often go undi-
agnosed until they present as overt heart and renal failure. There-
fore, early detection and medical intervention are important
clinical issues.
The renin–angiotensin aldosterone system plays an essential
role in the pathophysiology of diabetes-related complications14.
Angiotensin II receptor blockers (ARBs) can slow microvascular
complications of DM, and prevent myocardial dysfunction
or ﬁbrosis15–17. Peroxisome proliferator-activated receptor
(PPAR)-gamma agonists have a well-established therapeutic role
for treating type 2 diabetes. PPAR-gamma agonists show
favorable metabolic effects, and can attenuate microalbuminuria
in these patients18. However, they also cause ﬂuid retention,
thereby increasing the risk of heart failure19. Because
ARBs and PPAR-gamma agonists are commonly used in
combination, it is important to clarify the combinatorial effects
these two drugs have on myocardial and renal microan-
giopathies.
The Ostuka Long-Evans Tokushima Fatty (OLETF) rat is a
useful animal model that manifests clinical and pathological
features of DM resembling those of human type 2 diabe-
tes20,21. The Long-Evans Tokushima Otsuka (LETO) rats are
lean, non-diabetic control rats that have been established
from the same original colony as the OLETF rat20. It has
been shown that overt diabetes in the OLETF rats develops
at approximately 20–28 weeks-of-age20. Furthermore, the
metabolic abnormalities and the alteration in LV function
become more prominent at approximately 28 weeks-of-age21.
Therefore, using the OLETF rats at 28 weeks-of-age, we inves-
tigate the effects of rosiglitazone (a PPAR-gamma agonist)
and losartan (an ARB) on myocardial function, struc-
tural changes in the myocardium and microvasculature, and
the association between these drugs and the degree of
microalbuminuria.
MATERIALS AND METHODS
Experimental Animals
All procedures were in accordance with institutional guidelines
for animal research. A total of 20 male OLETF rats, which are
established as spontaneously long-term hyperglycemic rats with
type 2 diabetes, and ﬁve male LETO rats aged 4 weeks were
obtained from the Tokushima Research Institute of Otsuka Phar-
maceutical Co. (Japan). All animals were maintained in an ani-
mal facility with ventilation, controlled temperature (22 – 2°C),
and a 12-h light/dark cycle (lights on at 08.00 hours). Animals
were housed in plastic cages (n = 2 per cage), and were fed ad
libitum with standard chow diet and tap water.
OLETF rats were randomly divided into four groups (n = 5
per group) at 28 weeks-of-age, and treated with vehicle
(untreated OLETF, n = 5); an ARB (OLETF rats treated with
losartan, n = 5); a PPAR-gamma agonist (OLETF rats treated
with rosiglitazone, n = 5); or a combination of both drugs
(OLETF rats treated with losartan and rosiglitazone, n = 5).
LETO rats were treated with vehicle (untreated LETO, n = 5).
The ARB, losartan (Merck & Co., Readington Township, NJ,
USA) was given at the dose of 5 mg/kg bodyweight per day by
oral gavage. The PPAR-gamma agonist, rosiglitazone (Glaxo-
SmithKline plc., London, UK) was given at the dose of 3 mg/
kg bodyweight per day, also by oral gavage for a subsequent
12 weeks.
Blood Chemistry and Urinalysis
Urine samples and blood samples were collected at 28 and
40 weeks-of-age. Samples were collected in metabolic cages. At
the end of the experimental period (at 40 weeks-of-age), the
animals were anesthetized, and the trunk blood was collected
to measure serological parameters. Plasma glucose levels were
measured using the glucose oxidase method. Plasma insulin
concentrations were measured by a radioimmunoassay using a
double-antibody method. Total plasma cholesterol, triglyceride,
high-density lipoprotein and low-density lipoprotein levels were
measured by an enzymatic colorimetric method. For measuring
fasting plasma glucose levels and plasma insulin concentrations,
blood samples were obtained after overnight fasting.
Reverse Transcription Polymerase Chain Reaction
Isolation of Total Ribonucleic Acid
Total ribonucleic acid (RNA) was extracted by 500 lL/60-mm
plate Tri-reagent (Sigma, St. Louis, MO, USA). Approximately
100 lL of chloroform was added to the Tri-reagent. The sam-
ple was vortexed for approximately 10 s. The sample was then
centrifuged at 12,000 g at 4°C for 15 min. Three layers
appeared in the tube. The transparent upper layer was collected
into a new tube. Approximately 250 lL 2-propanol was poured
over the sample followed by 30 s of vortexing. This sample was
centrifuged at 12,000 g at 4°C for 10 min. The supernatant was
discarded. The remaining pellet was washed with 75% ethanol
(Duksan, Seoul, Korea) and mixed with diethylpyrocarbonate
(DEPC; Sigma) water. This sample was centrifuged at 7,500 g
at 4°C for 5 min. The supernatant was discarded, and the pellet
was dried at room temperature for approximately 7 min.
Finally, 30 lL of nuclease-free water was added to the pellet.
The quality and quantity of the RNA were determined by
OD260/OD280 on a DU 640 spectrophotometer (Effendorf,
Hamburg, Germany.)
Complementary Deoxyribonucleic Acid Synthesis
Complementary deoxyribonucleic (cDNA) was synthesized with
RT-&GOTM (MPbio, Eschwege, Germany). Then, 1 lg of total
RNA was added to 1 lL anchored primer (dT)25V, 2 lL dith-
iothreitol and 6 lL of nuclease-free water (9 lL total). To
prevent secondary structures, the mixture was incubated for
5 min at 70°C, and 8 lL RT-&GOTM mastermix was added.
The sample was incubated at 42°C for 1 h. At the conclusion,
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the reverse transcriptase was inactivated at 70°C for 15 min.
cDNA quality and quantity were determined by OD260/OD280
with a DU 640 spectrophotometer.
Polymerase Chain Reaction Analysis
One microgram of cDNA, 10 pmol/L primer of each primer
(forward and reverse; Table 1), 0.1 mmol/L deoxynucleotide
(dNTP) mixture, 1.25 U of Taq polymerase and 10 9 reaction
buffer were mixed with nuclease-free water to a total volume of
25 lL. The polymerase chain reaction (PCR) conditions were
ﬁxed as follows: a cycle of denaturing at 94°C for 3 min,
followed by 35 cycles of: denaturation at 94°C for 30 s, anneal-
ing at 48–60°C for 30 s and elongation at 72°C for 30 s. The
sample was the kept at 72°C for 10 min. When the PCR assay
ﬁnished, the PCR product was separated by electrophoresis on
a 1.2% agarose gel (Biorad, Hercules, CA, USA), and visualized
on a Gel-Doc (Biorad) system after staining with ethidium
bromide (EtBr; Sigma).
Histological Examination
At the end of the experimental period (at 40 weeks-of-age),
hearts were rapidly excised and weighed after exsanguination.
The heart was perfusion-ﬁxed with 10% (v/v) neutral buffered
formaldehyde for 24 h, transversely sectioned into four 5-lm
thick sections and embedded in parafﬁn by routine methods.
Sections were mounted on gelatin-coated glass slides to ensure
different stains could be used on successive sections. After
deparafﬁnization and rehydration, the sections were stained
with Masson’s trichrome staining to assess cytological details,
such as interstitial ﬁbrosis. Interstitial ﬁbrosis area was mea-
sured with MetaMorph software version 4.6 (Universal Imaging
Corp., Downingtown, PA, USA).
Immunohistochemistry for Collagens
Histological analysis was carried out according to the instruc-
tions of the manufacturer (R.T.U VECTASTAIN Universal
Quick Kit; Vector Laboratories, Inc., Burlingame, CA). In
brief, the excised heart tissues were ﬁxed in 3.7% buffered
formaldehyde and embedded in parafﬁn. Tissue sections, 5-
lm thick, were deparafﬁnized, rehydrated and rinsed with
phosphate-buffered solution. Sodium citrate antigen retrieval
was carried out in 10 mmol/L sodium citrate (pH 6.0) in a
microwave for 10 min. Sections were incubated in 3% H2O2
in order to quench endogenous peroxidase. The sample was
blocked in 2.5% normal horse serum, and incubated in pri-
mary antibodies (anti-type I collagen 1:100: Southern Biotech-
nology Associates Inc., Birmingham, AL, USA; anti-type III
collagen antibody: Biogenex, San Ramon, CA, USA). Heart
sections were treated with biotinylated pan-speciﬁc universal
secondary antibody and streptavidin/peroxidase complex
reagent. Using a DAB substrate kit, the heart sections were
stained with antibody. Sections were counterstained with 1%
methyl green, and dehydrated with 100% N-butanol (Duksan),
ethanol and xylene (Duksan).
Evaluation of Cardiac Function
Two-Dimensional Echocardiography
Transthoracic echocardiographic studies were carried out on a
GE Vivid 7 ultrasound machine (GE Medical System, Schenec-
tady, NY, USA) with a 10.0-MHz transducer at 28 weeks-of-
age (before randomization of groups) and at 40 weeks-of-age
(at the end of the experimental period) by an experienced cardi-
ologist who was blinded to all groups. The rats were anesthe-
tized with inhaled isoﬂurane. The chest was shaved, and the
rats were placed in the left lateral decubitus position. The trans-
ducer was placed on the left hemithorax, and short axis views
were recorded. Two-dimensional images were obtained at the
mid-papillary level. An M-mode tracing of left ventricular (LV)
contraction was also obtained at the same level as the short-axis
view. The LV end diastolic dimension and LV end systolic
dimension were measured by M-mode tracing. These parame-
ters allowed the LV fractional shortening and ejection fraction
to be calculated. Two images were obtained in each view, and
each parameter was measured in each of three consecutive beats
per image. Six values of each parameter were measured, and
the average was recorded.
Strain and Strain Rate Imaging
Echocardiographic images were stored digitally and analyzed off-
line with EchoPAC 6.3.0 software (GE Vigmed, Horten, Norway).
More than three images were obtained in the short axis view at
the mid-LV level, and the parameters were measured in each of
three consecutive beats per image. The peak radial systolic strain
and systolic strain rates at six segments (anteroseptum, anterior,
Table 1 | Primer sequences for reverse transcription polymerase chain reaction analysis
Primer Sequence (5′ ? 3′) Primer Sequence (5′ ? 3′)
IL-1b TGACCCATGTGAGCTGAAAG IL-6 GACTGATGTTGTTGACAGCCACTGC
AGGGATTTTGTCGTTGCTTG TAGCCACTCCTTCTGTGACTCTAACT
TGF-b CTTCAGCTCCACAGAGAAGAACTGC TNF-a GTAGCCCACGTCGTAGCAAA
CACGATCATGTTGGACAACTGCTCC CCCTTCTCCAGCTGGGAGAC
18s rRNA GTCCCCCAACTTCTTAGAG
CACCTACGGAAACCTTGTTAC
IL, interleukin; rRNA, ribosomal ribonucleic acid; TGF, transforming growth factor; TNF, tumor necrosis factor.
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anterolateral, posterolateral, inferior and inferoseptum) were
analyzed. For quantitative analysis of global LV systolic function,
the average values from six segments of the LV were calculated.
Statistical Analysis
Values are expressed as mean – standard deviation. One
way-analysis of variance followed by Tukey’s test for multiple
comparisons was used to compare experimental groups.
A P-value <0.05 was considered signiﬁcant. Statistical analysis
was carried out using SPSS 13.0 software (SPSS, Chicago, IL,
USA).
RESULTS
Body and Heart Weight
The OLETF rats showed a signiﬁcantly higher bodyweight
compared with the LETO rats at both 28 and 40 weeks-of-age.
Table 2 | Data of bodyweight and heart weight at baseline and after treatment
LETO
(n = 5)
OLETF (n = 20)
Control
(n = 5)
LOS
(n = 5)
ROS
(n = 5)
LOS + ROS
(n = 5)
Bodyweight (g)
At 28 weeks 504 – 14 548 – 14* 552 – 37* 549 – 25* 561 – 38*
At 40 weeks 511 – 31 616 – 40* 571 – 27*† 645 – 42*† 612 – 31*
Changes 7 – 7 67 – 25* 20 – 13*† 97 – 22*† 51 – 30*
Heart weight (gram) 2.0 – 0.1 2.0 – 0.1 2.1 – 0.1 2.4 – 0.1 2.3 – 0.2
LV/heart weight 0.7 – 0.0 0.7 – 0.1 0.7 – 0.0 0.7 – 0.1 0.7 – 0.1
LOS, Otsuka Long-Evans Tokushima Fatty rats treated with losartan; LOS + ROS, Otsuka Long-Evans Tokushima Fatty rats treated with losartan and
rosiglitazone; LV, left ventricular; OLETF, Otsuka Long-Evans Tokushima Fatty rats; ROS, Otsuka Long-Evans Tokushima Fatty rats treated with rosiglit-
azone. *P < 0.05, compared with the untreated Long-Evans Tokushima Otsuka (LETO) rats. †P < 0.05, compared with controls.
Table 3 | Data of plasma glucose, insulin, lipids and urine albumin/creatinine ratio at baseline and after treatment
LETO
(n = 5)
OLETF (n = 20)
Control
(n = 5)
LOS
(n = 5)
ROS
(n = 5)
LOS + ROS
(n = 5)
At 28 weeks
Glucose (mg/dL) 92 – 12 124 – 20* 126 – 17* 129 – 25* 128 – 21*
Insulin (ng/mL) 1.9 – 0.8 6.1 – 1.9* 5.9 – 1.0* 6.9 – 2.6* 5.9 – 1.3*
Total Chol (mg/dL) 93 – 5 102 – 11 99 – 13 104 – 15 102 – 10
Triglyceride (mg/dL) 21 – 10 33 – 15 31 – 14 33 – 17 32 – 9
HDL Chol (mg/dL) 25 – 4 25 – 9 24 – 7 24 – 8 25 – 6
LDL Chol (mg/dL) 14 – 1 17 – 2 16 – 3 17 – 3 15 – 1
Urine Alb (mg/dL) 0.3 – 0.2 0.7 – 0.3* 0.9 – 0.5* 0.8 – 0.5* 0.7 – 0.4*
Urine Cr (mg/dL) 88 – 45 97 – 81 114 – 54 118 – 61 94 – 75
Urine Alb/Cr 3.4 – 0.7 7.8 – 8.8* 7.9 – 4.2* 6.8 – 3.8* 7.4 – 5.0*
At 40 weeks
Glucose (mg/dL) 103 – 12 161 – 31* 153 – 23* 130 – 30*† 129 – 18*†
Insulin (ng/mL) 2.4 – 1.0 9.8 – 3.0* 7.0 – 1.6* 4.6 – 2.6† 3.8 – 1.0†
Total Chol (mg/dL) 93 – 5 98 – 18 103 – 4 104 – 13 101 – 13
Triglyceride (mg/dL) 21 – 10 112 – 25 55 – 17 39 – 17 35 – 4
HDL Chol (mg/dL) 25 – 4 24 – 2 23 – 5 27 – 9 22 – 2
LDL Chol (mg/dL) 14 – 1 23 – 6 18 – 1 18 – 2 16 – 3
Urine Alb (mg/dL) 0.5 – 0.1 8.2 – 0.8* 4.8 – 0.2* 4.5 – 1.3* 3.6 – 0.1*
Urine Cr (mg/dL) 95 – 81 168 – 47 178 – 172 120 – 120 109 – 98
Urine Alb/Cr 5.4 – 2.8 77.4 – 58.1* 32.0 – 12.9*† 45.9 – 72.5*† 27.7 – 22.3*†
Alb, albumin; Chol, cholesterol; Cr, creatinine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LOS, Otsuka Long-Evans Tokushima Fatty
rats treated with losartan; LOS + ROS, Otsuka Long-Evans Tokushima Fatty rats treated with losartan and rosiglitazone; OLETF, Otsuka Long-Evans
Tokushima Fatty rats; ROS, Otsuka Long-Evans Tokushima Fatty rats treated with rosiglitazone. *P < 0.05, compared with the untreated Long-Evans
Tokushima Otsuka (LETO) rats. †P < 0.05, compared with controls.
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The bodyweight of the OLETF rats treated with rosiglitazone
was higher than the three other OLETF groups. This difference
might be explained by rosiglitazone-induced weight gain. There
were no signiﬁcant differences in either the heart weight or LV/
heart weight ratio among groups (Table 2).
Plasma Glucose, Insulin and Degree of Albuminuria
The OLETF rats showed elevated fasting glucose levels, fast-
ing insulin levels and urine albumin/creatinine ratios com-
pared with the LETO rats. This difference was apparent at
both 28 and 40 weeks-of-age. There were no signiﬁcant dif-
ferences in these serological and urinary parameters among
the groups of OLETF rats at 28 weeks. At 40 weeks, favor-
able metabolic proﬁles were observed in the rosiglitazone
group and in the combination group compared with the
untreated or the losartan group. The losartan-treated and the
combination drug-treated OLETF rats showed a signiﬁcant
attenuation in the progression of albuminuria. The rosiglitaz-
one group also had a lower level of urine albumin compared
with the untreated group, but the degree of albuminuria was
higher than the losartan-treated or combination drug-treated
group (Table 3).
Expression of Cytokine Genes in Cardiac Tissue
When we compared the expression levels of myocardial cytokine
genes using reverse transcription PCR analysis, the growth fac-
tors, transforming growth factor-b and tumor necrosis factor-a,
along with the pro-inﬂammatory cytokines, interleukin (IL)-1b
and IL-6, were signiﬁcantly higher in the OLETF rats compared
with the LETO rats. However, the expression of each gene was
signiﬁcantly attenuated in the losartan-treated and combination
groups (two- and fourfold, respectively) when compared with
the untreated OLETF rats. After being treated with losartan or
with the combination treatment, the expression of cytokine
genes in the OLETF cardiac tissue was similar to that of the
LETO cardiac tissue. The data are presented in Figure 1.
Myocardial Fibrosis and Collagen Interposition
Figure 2 shows the myocardial histological ﬁndings and the
degree of interstitial ﬁbrosis in the experimental animals. The
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Figure 1 | Expression levels of cytokine genes determined by reverse transcription polymerase chain reaction among the groups. Cont, control;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin; LETO, Long-Evans Tokushima Otsuka rats; Los, losartan; OLETF, Otsuka Long-
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untreated OLETF rats showed a higher proportion of interstitial
ﬁbrosis in the myocardium compared with the LETO rats.
Interstitial ﬁbrosis was attenuated by approximately 3% in the
OLETF rats treated with losartan and the combination treatment
compared with the untreated OLETF rats. This attenuation was
minimal in the OLETF rats treated with rosiglitazone alone.
Type I and III collagen interposition in the LV was more
prominent in the untreated OLETF controls (Figure 3). In the
groups treated with losartan or the combination treatment, col-
lagen interposition was similar to that observed in the LETO
rats.
Myocardial Function
Table 4 shows the functional data from two-dimensional echo-
cardiography and strain rate imaging at baseline and after treat-
ment. At 28 weeks, the end-systolic dimension was slightly
larger in the OLETF rats compared with the LETO rats, but
this difference was not statistically signiﬁcant. Although there
were no differences in the LV ejection fraction, the global radial
strain and strain rate assessed with strain rate imaging were sig-
niﬁcantly lower in OLETF rats. Therefore, there was subtle LV
systolic dysfunction in diabetic rats at the age of 28 weeks.
After 12 weeks of treatment, LV structure and functional
abnormalities were attenuated in rats treated with drugs. The
LV progressively dilated, and myocardial function was more
depressed in the untreated OLETF rats at the same time-point.
In the OLETF rats treated with losartan or the combination of
both drugs, the global radial strain, strain rate, LV ejection frac-
tion and chamber size were similar to those observed in the
untreated LETO rats. However, increased heart size and
reduced systolic function were observed in the OLETF rats
treated with rosiglitazone. These ﬁndings suggest that treatment
with rosiglitazone alone does not confer protection from pro-
gressive myocardial dysfunction in diabetic rats. However, it is
important to note that the combination of both drugs does
protect against progressive myocardial dysfunction.
DISCUSSION
The results of the present study show the following: (i) losartan
(an ARB) and rosiglitazone (a PPAR-c agonist) have differen-
tial effects on myocardial function, as well as structural changes
of myocardium; and (ii) myocardial changes are associated
with the degree of microalbuminuria in a rat model of type 2
diabetes.
The development of myocardial dysfunction is a major
complication of DM. This condition is characterized by
defects in contractile and relaxation functions in the absence
of signiﬁcant coronary artery disease or systemic hyperten-
sion2. In the past three decades, a number of experimental,
pathological, epidemiological and clinical data have conﬁrmed
the association of DM with myocardial dysfunction8–12. The
pathogenesis of myocardial dysfunction in DM remains unclear,
although several mechanisms, including metabolic disturbances,
myocardial ﬁbrosis, microangiopathy, autonomic dysfunction
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and insulin resistance, have been proposed. Changes in the
microvascular structure and function are also considered an
important mechanism.
Albuminuria is considered a marker of generalized vascular
dysfunction3. It has been shown to predict cardiovascular
morbidity and mortality in diabetic patients independent of
conventional cardiovascular risk factors including age, arterial
hypertension, and hypercholesterolemia4–7. Although the under-
lying mechanism linking albuminuria to cardiac dysfunction is
not clear, it is possible that the vascular changes that lead to
(a) (b)
(c) (d)
(f) (g)
(h) (i) (j)
(e)
Figure 3 | Interposition of collagen fibers in experimental animals. (a–e) Collagen type I. (a) Long-Evans Tokushima Otsuka rats (LETO). (b) Otsuka
Long-Evans Tokushima Fatty (OLETF) control rats. (c) OLETF rats given losartan. (d) OLETF rats given rosiglitazone. (e) OLETF rats given losartan and
rosiglitazone. (f–j) Collagen type III. (f) Long-Evans Tokushima Otsuka rats (LETO). (g) Otsuka Long-Evans Tokushima Fatty (OLETF) control rats. (h)
OLETF rats given losartan. (i) OLETF rats given rosiglitazone. (j) OLETF rats given losartan and rosiglitazone.
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renal dysfunction might also present in the vasculature of
the heart, thus contributing to cardiac dysfunction. In diabetic
hearts, morphological changes of small vessels characterized by
microangiopathy were seen in several animal and autopsy stud-
ies9,10. In a previous clinical study, we showed that Doppler
strain and strain rate imaging could detect subclinical LV
systolic and diastolic dysfunction in diabetic patients with
albuminuria13. In addition, it was proven that albuminuria
was associated with myocardial dysfunction in diabetic patients
without overt heart disease13,22. In the present study, the differ-
ent degrees of microalbuminuria among the groups corre-
sponded not only with the severity of LV systolic dysfunction
assessed by strain and strain rate imaging, but also histological
ﬁndings of myocardial ﬁbrosis and collagen interposition.
Angiotensin II plays a key pathophysiological role in the
progression of diabetic renal disease, and blockade of the renin–
angiotensin system with angiotensin converting enzyme inhibi-
tors or ARBs has become an important therapeutic strategy to
reduce adverse renal and cardiovascular events in DM patients23–
25. PPARs are ligand-activated nuclear transcription factors that
have been shown to play important roles in maintaining glucose
and lipid homeostasis. Thiazolidinediones might modify the risk
of vascular complications in DM, raise high-density lipoprotein
cholesterol levels and lower triglycerides. It was reported that
PPAR-alpha and -gamma agonists attenuate diabetic kidney dis-
ease in apolipoprotein E knockout mouse, and rosiglitazone
improves both plasma glucose and blood pressure levels18,26. The
beneﬁcial effects of thiazolidinediones on hyperglycemia and car-
diovascular risk factors have made them attractive therapeutic
agents for patients with type 2 diabetes. However, in clinical
practice, edema frequently occurs in patients treated with rosiglit-
azone, and signs of heart failure can develop as a side-effect. This
is despite many animal experimental studies that have shown the
beneﬁcial effects of reducing LV collagen accumulation and
improving LV function19,27–30. In an effort to resolve this discrep-
ancy, the present study clariﬁed that rosiglitazone failed to pre-
vent the progression of myocardial dysfunction, even though it
promoted favorable metabolic proﬁles. In the present study, we
could see the relatively dilated LV end-systolic dimensions in
the rosiglitazone-treated group. Therefore, we postulated that the
negative results of PPAR-gamma agonists on the improvement
of global radial strain, ﬁbrosis and cardiac function might be
due to abnormal accumulation of interstitial ﬂuid. Hao et al.31
showed the effects of PPAR-gamma ligands on angiotensin II-
induced plasminogen activator inhibitor-1 and extracellular
matrix expression assessed in primary-cultured rat cardiac ﬁbro-
blasts, and also revealed consistent results in angiotensin II-
infused rats as the in vivo model. Although the discrepancy
between the previous study and the present ﬁndings is difﬁcult
to explain, the present study seems to be more physiological and
closer to the real clinical situation. In contrast, the combination
of losartan and rosiglitazone showed synergistic effects on the
prevention of myocardial dysfunction and histological progres-
sion. These results suggest that PPAR-gamma agonists promote
favorable metabolic proﬁles, and they might be safe and valuable
in the treatment of heart failure by combining with ARBs.
The limitations of the present study must be addressed. First,
the hemodynamic parameters, such as blood pressure and
LV pressure, were not evaluated, so we could not completely
exclude the adverse effects of high blood pressure on the
Table 4 | Myocardial functional assessment with two-dimensional echocardiography and strain rate imaging at baseline and after treatment
LETO
(n = 5)
OLETF (n = 20)
Control
(n = 5)
LOS
(n = 5)
ROS
(n = 5)
LOS + ROS
(n = 5)
At 28 weeks
LVEDD (mm) 7.6 – 0.2 8.0 – 0.5 7.9 – 0.4 8.0 – 0.5 8.1 – 0.6
LVESD (mm) 5.6 – 0.4 5.8 – 0.5 5.7 – 0.4 5.8 – 0.6 5.9 – 0.4
FS (%) 26.4 – 2.1 24.0 – 2.8 23.2 – 3.2 23.6 – 2.9 23.6 – 1.9
LVEF (%) 60.1 – 4.3 58.7 – 5.0 62.8 – 4.8 61.0 – 5.4 58.5 – 4.2
Global radial strain (%) 60.1 – 5.8 52.8 – 8.1* 50.2 – 5.5* 49.8 – 6.1* 53.7 – 8.0*
Global radial strain rate (/s) 9.7 – 1.2 8.5 – 2.1* 8.8 – 3.6* 8.9 – 1.9* 8.3 – 2.6*
At 40 weeks
LVEDD (mm) 7.7 – 0.3 8.2 – 0.5* 7.5 – 0.4† 7.7 – 0.3† 7.5 – 0.5†
LVESD (mm) 5.7 – 0.5 5.9 – 0.3 5.4 – 0.4† 6.3 – 0.6† 5.0 – 0.6†
FS (%) 25.6 – 2.6 23.2 – 2.7* 28.2 – 2.3*† 24.9 – 5.1 30.3 – 4.8*†
LVEF (%) 58.1 – 4.0 55.3 – 5.9 60.3 – 3.9† 54.0 – 7.4* 61.6 – 5.2†
Global radial strain (%) 55.5 – 7.0 44.3 – 10.5* 59.3 – 6.7† 49.8 – 6.0* 55.7 – 4.5†
Global radial strain rate (/s) 8.5 – 1.9 7.8 – 2.7* 8.8 – 2.6† 7.9 – 1.5* 8.5 – 2.1†
FS, fractional shortening; LOS, Long-Evans Tokushima Fatty rats treated with losartan; LOS + ROS, Otsuka Long-Evans Tokushima Fatty rats treated
with losartan and rosiglitazone; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end
systolic dimension; ROS, Otsuka Long-Evans Tokushima Fatty rats treated with rosiglitazone. *P < 0.05, compared with the untreated Long-Evans
Tokushima Otsuka (LETO) rats. †P < 0.05, compared with controls.
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diabetic myocardium. Second, we were not able to show the
diastolic dysfunction with Doppler-based velocities in OLETF
rats, although diastolic dysfunction has been described as an
early sign of diabetic cardiomyopathy preceding the systolic
damage in diabetic patients32,33. It was difﬁcult to assess mitral
inﬂow from rats because of their rapid heart rates and the
angle-dependence of the Doppler velocity. Third, this experi-
mental study was carried out with a small number of LETO
and OLETF rats.
In conclusion, losartan confers protective cardiovascular effects
by attenuating the progression of microalbuminuria, along with
myocardial structural and functional changes in OTLEF rats. In
contrast, although rosiglitazone treatment in these rats promoted
favorable metabolic beneﬁts, it had only a minimally protective
effect against the progression of microalbuminuria, and no bene-
ﬁt on myocardial structural and functional was observed. The
combination of losartan and rosiglitazone showed both meta-
bolic beneﬁts and myocardial protective effects.
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